

In accordance with 37 C.F.R. § 1.121, please substitute for claims 20 and 21 the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

20. (2X Amended) A method for treating leukemia comprising administering to a person in need thereof of an effective amount of a monoclonal antibody or a fragment thereof that specifically recognizes and binds to an Integrin Associated Protein (IAP), wherein said binding of said monoclonal antibody or said fragment thereof induces apoptosis of nucleated blood cells.

21. (Amended) The method according to claim 20, wherein said IAP is of human origin.

Please add the following new claims:

--24. (NEW) The method according to claim 20, wherein said leukemia is myeloid leukemia or lymphoid leukemia.

25. (NEW) The method according to claim 20, wherein said effective amount is in the range of 5 µg to 500 mg/kg.--

REMARKS

Status of the Claims

By this amendment, claims 13-19 are canceled, claims 20 and 21 are amended and claims 24 and 25 are added. Accordingly, upon entry of this Amendment, claims 20, 21 and 24 and 25 will remain pending in the application.

Exemplary support for the amendments to claims 20 and 21 is found in the specification on page 16, line 19-21; page 17, lines 7-13 and Example 5. Exemplary support for claim 24 is found in the specification on page 16, lines 19-21. Exemplary support for claim 25 is found in the specification on page 17, lines 7-13.